Abstracts Archive - Page 1119 of 2607 - ACR Meeting Abstracts

Abstract Number: 2684 • 2019 ACR/ARP Annual Meeting
Real-world Comparative Study of Methotrexate vs Tocilizumab in Patients with Giant Cell Arteritis with Large Vessel Involvement
DIANA PRIETO- PENA¹, Mónica Calderón-Goercke ², Javier Loricera ³, Javier Narváez ⁴, Elena Aurrecoechea ⁵, Ignacio Villa ⁶, Santos Castañeda ⁷, Catalina Gómez-Arango ⁸, Antonio Mera ⁹, Eva Perez Pampín ⁹, Vicente Aldasoro Caceres ¹⁰, N Alvarez Rivas ¹¹, N Fernandez Llanio ¹², María Álvarez del buergo ¹³, Luisa Marena-Rojas ¹⁴, Francisca Sivera ¹⁵, Eva Galindez-Agirregoikoa ¹⁶, Roser Solans-Laqué ¹⁷, Susana Romero-Yuste ¹⁸, Lara Sanchez-Bilbao ¹⁹, Iñigo Gonzalez-Mazon ¹, Isabel Martínez Rodríguez ²⁰, Ignacio Banzo ²⁰, Miguel Angel González-Gay ²¹ and Ricardo Blanco ¹⁹, ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ³Rheumatology Department. Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, Barcelona, Catalonia, Spain, ⁵Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ⁶Hospital de Sierrallana, Torrelavega, Cantabria, Spain, ⁷Rheumatology Department, Hospital Universitario de la Princesa, IIS-Princesa, Madrid, Spain, Madrid, Spain, ⁸Hospital Alto Deba, Mondragon, Pais Vasco, Spain, ⁹Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹⁰Complejo Hospitalario de Navarra, Navarra, Navarra, Spain, ¹¹H. Lucus Augusti, Lugo, Spain, ¹²H. Arnau de Vilanova, Lerida, Spain, ¹³Hospital Río Carrión, Palencia, Castilla y Leon, Spain, ¹⁴Hospital La Mancha Centro, Alcázar de San Juan, Castilla-La Mancha, Spain, ¹⁵Hospital General Universitario de Elda, Elda, Spain, ¹⁶Hospital de Basurto, Bilbao, Pais Vasco, Spain, ¹⁷Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain., Barcelona, Catalonia, Spain, ¹⁸Complejo Hospitalario Universitario Pontevedra, Pontevedra, Galicia, Spain, ¹⁹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Universidad de Cantabria and IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Giant cell arteritis (GCA) is the most common large vasculitis in elderly patients. According to previous studies, 50% of patients with GCA in whom…
Abstract Number: 2685 • 2019 ACR/ARP Annual Meeting
Factors Contributing to Capturing Positive Findings on Temporal Artery Biopsy: An Australian Experience from Two Rheumatology Referral Centers
Victor Yang ¹, Benjamin Sutu ², Christopher McMaster ³, Claire Owen ¹, Alexander Strathmore ⁴, Gene-Siew Ngian ², Shereen Oon ⁴, Jessica Leung ¹, Ian Wicks ⁵, Russell Buchanan ¹ and David Liew¹, ¹Austin Health, Heidelberg, Victoria, Australia, ²Melbourne Health, Parkville, Victoria, Australia, ³Austin Health, Melbourne, Victoria, Australia, ⁴Melbourne Health, Melbourne, Victoria, Australia, ⁵Melbourne Health, Parkville, Australia
Background/Purpose: Temporal artery biopsy (TAB) is widely recognised as the diagnostic gold standard for GCA, despite having a poor sensitivity due to the presence of…
Abstract Number: 2686 • 2019 ACR/ARP Annual Meeting
Real Life Data over 4 Years from a Fast Track GCA Pathway in Coventry
Shirish Dubey¹, Jonathan Pinnell ², Carl Tiivas ¹, Kaushik Chaudhuri ¹ and Purnima Mehta ¹, ¹University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom, ²University Hospital North Staffordshire NHS Trust, Stoke, United Kingdom
Background/Purpose: University Hospital Coventry and Warwickshire NHS Trust (UHCW) established its one stop Fast Track Pathway (FTP) for Giant Cell Arteritis (GCA) in 2013. It…
Abstract Number: 2687 • 2019 ACR/ARP Annual Meeting
Clinicopathologic Associations in a Large International Cohort of Patients with Giant Cell Arteritis
Michael Putman¹, K Bates Gribbons ², Anthea Craven ³, Cristina Ponte ⁴, Joanna Robson ⁵, Ravi Suppiah ⁶, Richard Watts ⁷, Raashid Luqmani ³, Peter Merkel ⁸, Amy Archer ⁹ and Peter C. Grayson ¹⁰, ¹Northwestern University, Chicago, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ⁵Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁶Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁷Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁸University of Pennsylvania, Pennsylvania, ⁹Northwestern, Chicago, ¹⁰National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: In addition to aiding in diagnosis, histopathologic findings from temporal artery biopsy (TAB) specimens in giant cell arteritis (GCA) may be valuable for their…
Abstract Number: 2688 • 2019 ACR/ARP Annual Meeting
Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, Joanna Robson ⁴, Ravi Suppiah ⁵, Raashid Luqmani ³, Richard Watts ⁶, Peter Merkel ⁷ and Peter C. Grayson ⁸, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁵Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Diagnostic assessment in giant cell arteritis (GCA) is rapidly changing as large-vessel (LV) involvement becomes increasingly recognized and non-invasive vascular imaging techniques become more…
Abstract Number: 2689 • 2019 ACR/ARP Annual Meeting
GM-CSF Pathway Signature Identified in Temporal Artery Biopsies of Patients with Giant Cell Arteritis
Maria C. Cid¹, Rohan Gandhi ², Marc Corbera-Bellalta ³, Nekane Terrades-Garcia ³, Sujatha Muralidharan ⁴ and John F Paolini ⁵, ¹Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ²Kiniksa Pharmaceuticals Corp., san diego, CA, ³Vasculitis Research Unit, Department of Autoimmune Diseases, University of Barcelona, Barcelona, Spain, ⁴Kiniksa Pharmaceuticals Corp., lexington, MA, ⁵Kiniksa Pharmaceuticals Corp, lexington, MA
Background/Purpose: Giant Cell Arteritis (GCA) is a type of large vessel vasculitis that can cause blindness and aortic aneurysms. A significant unmet medical need remains…
Abstract Number: 2690 • 2019 ACR/ARP Annual Meeting
Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience
Ingeborg Sacksen ¹, Elizabeth Jernberg ¹, Scott Pollock ², Jean Liew ³, Sarah Chung ², R Eugene Zierler ³ and Alison Bays², ¹University of Washington Division of Rheumatology, Seattle, ²University of Washington Division of Rheumatology, Seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults and if untreated, may result in visual impairment. Although the gold…
Abstract Number: 2691 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Gary Craig¹, Keith Knapp ², Bob Salim ³, Shalini Mohan ⁴ and Margaret Michalska ⁴, ¹Arthritis Northwest; Discus Analytics, Spokane, WA, ²Discus Analytics, Spokane, WA, ³Axio Research, Seattle, WA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: For patients with giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR), glucocorticoids are the mainstay of treatment. However, due to the chronic nature of…
Abstract Number: 2692 • 2019 ACR/ARP Annual Meeting
Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden
Pavlos Stamatis¹, Moman Mohammad ¹, Peter Merkel ², Martin Englund ³, Carl Turesson ⁴, David Erlinge ¹ and Aladdin Mohammad ¹, ¹Lund University, Lund, Skane Lan, Sweden, ²University of Pennsylvania, Philadelphia, PA, ³Lund University, Lund, Sweden, ⁴Lund University, Malmö, Sweden
Background/Purpose: The aim of this study was to estimate the incidence rate and prevalence of coronary artery diseases (CAD) in patients with temporal artery positive…
Abstract Number: 2693 • 2019 ACR/ARP Annual Meeting
Increasing Use of Biologics over Time in the First Year After Diagnosis of Systemic JIA Among Patients Enrolled in the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry
Ginger Janow¹, Timothy Beukelman ², Yukiko Kimura ³, Rayfel Schneider ⁴, Shalini Mohan ⁵, Gail Rodich ⁶ and Mary Beth Son ⁷, ¹Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, NJ, ²University of Alabama Birmingham, Birmingham, AL, ³Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵Genentech, Inc., South San Francisco, CA, ⁶Genentech, San Francisco, ⁷Boston Children's Hospital, Boston, MA
Background/Purpose: Prior to the development of anti-cytokine therapies, treatment for systemic juvenile idiopathic arthritis (SJIA) included high dose glucocorticoids and non-biologic disease modifying anti-rheumatic drugs…
Abstract Number: 2694 • 2019 ACR/ARP Annual Meeting
Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Rosemary Peterson¹, Rui Xiao ², Hannah Katcoff ¹, Brian Fisher ¹ and Pamela F. Weiss ¹, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: The effectiveness of IL-1 and IL-6 inhibitors as first-line therapy in patients with new-onset systemic JIA has led to the concept of a “window…
Abstract Number: 2695 • 2019 ACR/ARP Annual Meeting
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Manuela Pardeo¹, Claudia Bracaglia ², Anna Tulone ³, Antonella Insalaco ¹, Giulia Marucci ¹, Rebecca Nicolai ³, Virginia Messia ¹, Emanuela Sacco ⁴ and Fabrizio De Benedetti ⁵, ¹Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Lazio, Italy, ⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, ⁵Bambino Gesù Children’s Hospital, Rome, Italy
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) accounts for 10-20% of all patients with JIA. sJIA should be considered as a polygenic autoinflammatory disease. Interleukin 1…
Abstract Number: 2696 • 2019 ACR/ARP Annual Meeting
Long-Term Efficacy and Safety of Сanakinumab in Children with Systemic Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Rina Denisova ², Tatyana Dvoryakovskaya ², Ksenia Isaeva ², Ivan Kriulin ², Alina Alshevskaya ³ and Andrey Moskalev ³, ¹National Medical Research Center of Children`s Health, Moscow, Russia, ²NMRCCH, Moscow, Russia, ³Biostatistics and Clinical Trials Center, Novosibirsk, Russia
Background/Purpose: Canakinumab (CAN) is an efficacious option for treatment of systemic juvenile idiopathic arthritis (sJIA). However, it is still disputable whether long-term therapy is efficacious…
Abstract Number: 2697 • 2019 ACR/ARP Annual Meeting
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Simone Carbogno ¹, Denise Pires Marafon ², Giulia Marucci ³, Manuela Pardeo ³, Antonella Insalaco ³, Virginia Messia ³, Emanuela Sacco ⁴, Ferhat Demir ⁵, Betul Sozeri ⁵, Natasia Čekada ⁶, Marija Jelusic ⁷, Olga Vougiouka ⁸, Mikhail Kostik ⁹, Alenka Gagro ¹⁰, Christoph Kessel ¹¹, Francesca Minoia ¹², Fabrizio De Benedetti ¹³ and Claudia Bracaglia¹⁴, ¹Pediatric Area, University of Milan, Milan, Italy, Milan, Italy, ²Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, ⁵University of Health Sciences , Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ⁶Division of Paediatric Rheumatology and Immunology, University of Zagreb, Zagreb, Croatia, Zagreb, Croatia, ⁷University of Zagreb, Zagreb, Croatia, ⁸P. & A. Kyriakou Children’s Hospital, Athens, Greece, Athens, Greece, ⁹Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, Saint Petersburg, Russia, ¹⁰Children's Hospital Zagreb, Zagreb, Croatia, Zagreb, Croatia, ¹¹University Hospital Muenster, Muenster, Germany, ¹²Clinica De Marchi Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹³Bambino Gesù Children’s Hospital, Rome, Italy, ¹⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of rheumatic diseases in childhood, particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring in approximately…
Abstract Number: 2698 • 2019 ACR/ARP Annual Meeting
Reasons for Initiation of Canakinumab of Patients with Systemic Juvenile Idiopathic Arthritis: A Retrospective Medical Chart Review from the United States
Peter Hur¹, Raluca Ionescu-Ittu ², Ameur M. Manceur ², Kathleen G. Lomax ¹, Jordan Cammarota ³, Jipan Xie ⁴, Navneet Sanghera ⁵ and Alexei A. Grom ⁶, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Analysis Group, Inc., Montreal, QC, Canada, ³Analysis Group Inc.,, Washington, DC, ⁴Analysis Group, Inc., Los Angeles, CA, ⁵Novartis Pharmaceuticals Corporations, East Hanover, NJ, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a rare autoinflammatory disease characterized by fever and arthritis, often accompanied by rash. Canakinumab (CAN) was approved in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].